ProfileGDS5678 / 1434658_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 79% 81% 75% 81% 84% 83% 82% 80% 79% 79% 80% 80% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6480
GSM967853U87-EV human glioblastoma xenograft - Control 25.5788279
GSM967854U87-EV human glioblastoma xenograft - Control 35.7675781
GSM967855U87-EV human glioblastoma xenograft - Control 45.149375
GSM967856U87-EV human glioblastoma xenograft - Control 55.771981
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0273984
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8504383
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9719482
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6051380
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6179379
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4336479
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6564680
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7010280
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.450279